目的 通过网络药理学方法研究新型冠状病毒肺炎（COVID-19）中期诊疗方（XGZQZLF）治疗COVID-19的作用机制。方法 采用网络药理学方法，以中药系统药理学数据库、GeneCards数据库等为支撑，通过Cytoscape构建“药物-活性成分-靶点-疾病”网络，进一步进行基因富集分析和通路注释，研究XGZQZLF治疗COVID-19的物质基础和作用机制。结果 筛选出XGZQZLF有效成分80个，通过调控蛋白激酶（AKT1）、白细胞介素6（IL-6）、丝裂原活化蛋白激酶3（MAPK3）、血管内皮生长因子A（VEGFA）、半胱氨酸蛋白酶3（CASP3）等208个肺炎相关靶点，以及主要通过调控TNF信号通路、IL-17信号通路、Th17细胞分化、缺氧诱导因子1（HIF-1）信号通路等炎症和免疫相关通路发挥治疗COVID-19的作用。结论 XGZQZLF通过多成分、多靶点、多通路协同作用发挥治疗COVID-19的作用，为XGZQZLF治疗COVID-19的生物机制研究提供数据支撑，同时为COVID-19药物研发提供参考。

Objective To research the mechanism of Xinguanzhongqizhenliao formula (XGZQZLF) for COVID-19 treatment by network pharmacology. Methods "Drug-active ingredient-target-disease" network was constructed by Cytoscape based on TCMSP and GeneCards databases. Mechanism of XGZQZLF in treatment of COVID-19 was implemented by GO and KEGG analysis. Results A total of 80 active ingredients of XGZQZLF were screened out. They could regulate 208 targets of COVID-19, including AKT1, IL-6, MAPK3, VEGFA, CASP3 and so on, which exerted therapeutic effect on COVID-19 through regulating multiple signaling pathways such as TNF signaling pathway, IL-17 signaling pathway, Th17 cell differentiation, HIF-1 signaling pathway and so on. Conclusion XGZQZLF plays an important role in the treatment of COVID-19 through multi-component, multi-target and multi-pathway, which can provide reference for the synergistic theory of TCM compound prescription.

R285.5

国家重大新药创制项目（2018ZX09201011）；国家中医药管理局名老中医药专家传承工作室建设项目；北京中医药大学创新团队项目（2019-JYB-TD011）；中华中医药学会青年托举人才项目（QNRC2-A03）